There have been further developments in relation to Brexit that will be of interest to all stakeholders in the medicines supply chain to the United Kingdom and particularly pharma manufacturers (EMVO OBPs).
This information is usually available only to Regulatory Radar premium customers but we have chosen to make this available to all as a one-off.
This update explains further about the likely impact with regards to the EU -FMD and serialisation / traceability on all parties, and is available to download from our knowledge base.
To find out more about the Excellis Regulatory Requirements Radar and becoming a premium customer visit the Regulatory Requirements page here
Excellis Europe has successfully supported, from strategy to sustainability, a range of biotech/startups in US and Europe. We can help contact email@example.com and acheive success.